Castellan Group Halozyme Therapeutics, Inc. Transaction History
Castellan Group
- $236 Million
- Q3 2024
A detailed history of Castellan Group transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Castellan Group holds 113,798 shares of HALO stock, worth $5.34 Million. This represents 2.76% of its overall portfolio holdings.
Number of Shares
113,798
Previous 108,922
4.48%
Holding current value
$5.34 Million
Previous $5.7 Million
14.15%
% of portfolio
2.76%
Previous 2.85%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$827 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$606 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$312 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$191 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$160 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.54B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...